+ Follow Dr. Jorge Sison Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1678320
[Title] => Hangin sa MM mapanganib
[Summary] => Masyadong mapanganib sa mga naninirahan sa Metro Manila ang hangin na nalalanghap kumpara sa mga taga-lalawigan.
[DatePublished] => 2017-03-12 00:00:00
[ColumnID] => 0
[Focus] => 1
[AuthorID] => 1478575
[AuthorName] => Ludy Bermudo
[SectionName] => Bansa
[SectionUrl] => bansa
[URL] =>
)
[1] => Array
(
[ArticleID] => 568073
[Title] => Novartis gives more Filipino patients access to innovative hypertension treatment
[Summary] => Research-based Swiss healthcare company Novartis announced the inclusion of its novel anti-hypertension drug, aliskiren, in the company’s patient compliance program to give more Filipino patients access to the innovative treatment.
[DatePublished] => 2010-04-21 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Headlines
[SectionUrl] => headlines
[URL] =>
)
)
)
Dr. Jorge Sison
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1678320
[Title] => Hangin sa MM mapanganib
[Summary] => Masyadong mapanganib sa mga naninirahan sa Metro Manila ang hangin na nalalanghap kumpara sa mga taga-lalawigan.
[DatePublished] => 2017-03-12 00:00:00
[ColumnID] => 0
[Focus] => 1
[AuthorID] => 1478575
[AuthorName] => Ludy Bermudo
[SectionName] => Bansa
[SectionUrl] => bansa
[URL] =>
)
[1] => Array
(
[ArticleID] => 568073
[Title] => Novartis gives more Filipino patients access to innovative hypertension treatment
[Summary] => Research-based Swiss healthcare company Novartis announced the inclusion of its novel anti-hypertension drug, aliskiren, in the company’s patient compliance program to give more Filipino patients access to the innovative treatment.
[DatePublished] => 2010-04-21 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Headlines
[SectionUrl] => headlines
[URL] =>
)
)
)
abtest